By Ingmar Gorman, PhD
- Gorman, I., Nielson, E.M., Molinar, A., Cassidy, K., & Sabbagh, J. (2021) Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice. Front. Psychol. 12:645246. doi: 10.3389/fpsyg.2021.645246
- Gorman, I., Belser, A. B., Jerome, L., Hennigan, C., Shechet, B., Hamilton, S., … & Feduccia, A. A. (2020). Posttraumatic growth after MDMA‐assisted psychotherapy for posttraumatic stress disorder. Journal of Traumatic Stress, 33(2), 161-170.
- Winkler, P., Gorman, I., & Kočárová, R.(2016). Use of LSD by Mental Health Professionals. In Neuropathology of drug addictions and substance misuse (pp. 773-781). Academic Press.
- Gorman, I., (2015) Drug-assisted Psychotherapy. In Ingersoll, R. E., & Rak, C. F. (2015). Psychopharmacology for Mental Health Professionals: An Integrative Approach. Nelson Education.
- Fujáková, M., Páleníček, T., Brunovský, M.,Gorman, I., Tylš, F., Kubešová, A., … & Horáček, J. (2014). The effect of((−)-2-oxa-4-aminobicyclo [3.1. 0] hexane-2, 6-dicarboxylic acid (LY379268), anmGlu2/3 receptor agonist, on EEG power spectra and coherence in ketamine model of psychosis. Pharmacology Biochemistry and Behavior, 122, 212-221.
- Páleníček, T., Fujáková, M., Brunovský, M.,Horáček, J., Gorman, I., Balíková, M., … & Höschl, C. (2013). Behavioral, neurochemical and pharmaco-EEG profiles of the psychedelic drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in rats. Psychopharmacology, 225(1), 75-93.
- Páleníček, T., Fujáková, M., Brunovský, M.,Balíková, M., Horáček, J., Gorman, I., … & Krajča, V. (2011).Electroencephalographic spectral and coherence analysis of ketamine in rats: correlation with behavioral effects and pharmacokinetics. Neuropsychobiology, 63(4), 202-218.
By Elizabeth Nielson, PhD
- Nielson, E. M. Psychedelics as a Training Experience for Psychedelic Therapists: Drawing on History to Inform Current Practice. Journal of Humanistic Psychology. June 2021. doi:10.1177/00221678211021204
- Gorman, I., Nielson, E.M., Molinar, A., Cassidy, K., & Sabbagh, J. (2021) Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice. Front. Psychol. 12:645246. doi: 10.3389/fpsyg.2021.645246
- Tai, S. J.,Nielson, E. M., Lennard-Jones, M., Johanna Ajantaival, R. L., Winzer, R.,Richards, W. A., … & Malievskaia, E. (2021). Development and Evaluation of a Therapist Training Program for Psilocybin Therapy for Treatment-Resistant Depression in Clinical Research. Frontiers in Psychiatry, 12, 27.
- Nielson, E. M., May, D. G., Forcehimes, A. A.,& Bogenschutz, M. P. (2018). The psychedelic debriefing in alcohol dependence treatment: Illustrating key change phenomena through qualitative content analysis of clinical sessions. Frontiers in Pharmacology, 9, 132.
- Nielson, E. M., & Guss, J. (2018). The influence of therapists’ first-hand experience with psychedelics on psychedelic-assisted psychotherapy research and therapist training. Journal of Psychedelic Studies, 2(2), 64-73.
By Jeffrey Guss, MD
- Agin-Liebes, G. I., Malone, T.,Yalch, M. M., Mennenga, S. E., Ponté, K. L., Guss, J., … & Ross, S.(2020). Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. Journal of Psychopharmacology, 34(2), 155-166.
- Sloshower, J., Guss, J., Krause, R., Wallace, R. M.,Williams, M. T., Reed, S., & Skinta, M. D. (2020). Psilocybin-assisted therapy of major depressive disorder using Acceptance and Commitment Therapy as a therapeutic frame. Journal of Contextual Behavioral Science, 15, 12-19.
- Malone, T. C., Mennenga, S. E., Guss, J., Podrebarac, S.K., Owens, L. T., Bossis, A. P., … & Ross, S. (2018). Individual experiences in four cancer patients following psilocybin-assisted psychotherapy. Frontiers in Pharmacology, 9, 256.
- Nielson, E. M., & Guss, J. (2018). The influence of therapists’ first-hand experience with psychedelics on psychedelic-assisted psychotherapy research and therapist training. Journal of Psychedelic Studies,2(2), 64-73.
- Swift, T. C., Belser, A. B., Agin-Liebes, G., Devenot, N.,Terrana, S., Friedman, H. L., … & Ross, S. (2017). Cancer at the dinner table: experiences of psilocybin-assisted psychotherapy for the treatment of cancer-related distress. Journal of Humanistic Psychology, 57(5), 488-519.
- Belser, A. B., Agin-Liebes, G., Swift, T. C., Terrana, S.,Devenot, N., Friedman, H. L., … & Ross, S. (2017). Patient experiences of psilocybin-assisted psychotherapy: an interpretative phenomenological analysis. Journal of Humanistic Psychology, 57(4), 354-388.
- Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone,T., Cohen, B., … & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165-1180.
By Alan K Davis, PhD
- Davis, A. K., Barrett, F. S.,& Griffiths, R. R. (2020). Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. Journal of Contextual Behavioral Science, 15, 39-45.
- Garcia-Romeu, A., Davis, A. K., Erowid, F., Erowid, E., Griffiths, R. R., & Johnson, M. W. (2019). Cessation and reduction in alcohol consumption and misuse after psychedelic use. Journal of Psychopharmacology, 33(9), 1088-1101.
- Griffiths, R. R., Hurwitz, E. S., Davis, A. K., Johnson, M.W., & Jesse, R. (2019). Survey of subjective” God encounter experiences”: Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT. PloSone, 14(4).
- Davis, A. K., Barsuglia, J. P., Lancelotta, R., Grant, R.M., & Renn, E. (2018). The epidemiology of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption. Journal of Psychopharmacology,32(7), 779-792.
- Davis, A. K., & Rosenberg, H. (2017). Specific harm reduction strategies employed by 3, 4-methylenedioxymethamphetmine/ecstasy users in the United States and the United Kingdom. Drug Science, Policy and Law, 3, 2050324517711069.
- Davis, A. K., & Rosenberg, H. (2016). Using the Theory of Planned Behavior to predict implementation of harm reduction strategies among MDMA/ecstasy users. Psychology of Addictive Behaviors, 30(4), 500.
- Davis, A. K., Bonar, E. E., Ilgen, M. A., Walton, M. A.,Perron, B. E., & Chermack, S. T. (2016). Factors associated with having a medical marijuana card among Veterans with recent substance use in VA outpatient treatment. Addictive Behaviors, 63, 132-136.
- Davis, A. K., & Rosenberg, H. (2014). The prevalence, intensity, and assessment of craving for MDMA/ecstasy in recreational users. Journal of Psychoactive Drugs, 46(2), 154-161.
By Kelan Thomas, PhD
- Thomas, K., & Malcolm, B.(2021). Adverse Effects. Handbook of Medical Hallucinogens, 414.
- Thomas, K., Malcolm, B., & Lastra, D. (2017).Psilocybin-assisted therapy: A review of a novel treatment for psychiatric disorders. Journal of Psychoactive Drugs, 49(5), 446-455.
- Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C.,Abbas, A. I., Hufeisen, S. J., … & Roth, B. L. (2009). Predicting new molecular targets for known drugs. Nature, 462(7270), 175-181.
- Nguyen, L., Thomas, K. L., Lucke-Wold, B. P., Cavendish, J.Z., Crowe, M. S., & Matsumoto, R. R. (2016). Dextromethorphan: An update onits utility for neurological and neuropsychiatric disorders. Pharmacology & Therapeutics, 159, 1-22.
By Casey Paleos, PhD
- Ross, S., Bossis, A., Guss, J.,Agin-Liebes, G., Malone, T., Cohen, B., … & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165-1180.
- Paleos, C. A., & Ross, S. (2013). Ketamine: a light in the darkness. Multidisciplinary Association for Psychedelic Studies Bulletin, Special Edition, Spring, 28-33.